News

Public Health Vaccines & Institut Pasteur de Dakar announce strategic partnership around Marburg virus vaccine in Africa

December 19, 2025

News provided by EIN Presswire - Dec 18, 2025, 10:00 AM ET

PHV Logo PNG 

IPD LogoStrategic partnership enables manufacturing of PHV’s Marburg vaccine candidate (PHV01) at IPD’s flagship MADIBA facility and access to the vaccine in Africa.

We are thrilled to finalize this strategic partnership with IPD and enable long-term access to our important PHV01 candidate vaccine in Africa.”

— Michael McGinnis

"CAMBRIDGE, MA, UNITED STATES, December 18, 2025 /EINPresswire.com/ -- Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA, and Institut Pasteur de Dakar (IPD), a Senegalese not-for-profit foundation, today announced the formalization of a strategic partnership and licensing arrangement enabling technology transfer of PHV’s Marburg vaccine candidate (PHV01) to IPD’s flagship Vaccine Research Centre (VRC) and ultimately access to the vaccine in Africa. The Marburg virus, a close relative of Ebola that causes severe haemorrhagic fever and has a fatality ratio of up to 88%, is responsible for sporadic outbreaks, with the most recent occurring in Rwanda, Tanzania, and Equatorial Guinea. ..."

SEE: Public Health Vaccines & Institut Pasteur de Dakar announce strategic partnership around Marburg virus vaccine in Africa

https://fox59.com/business/press-releases/ein-presswire/876193805/public-health-vaccines-institut-pasteur-de-dakar-announce-strategic-partnership-around-marburg-virus-vaccine-in-africa/

Quick Links